Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02015910 · ClinicalTrials.gov registry record · Phase 4

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

A Phase 4 study, sponsored by Georgetown University.

Terminated
Registry status
Phase 4
Development phase
1
Enrollment target

NCT02015910 is a Phase 4 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02015910, a Phase 4 study, was terminated before completion, sponsored by Georgetown University.

TERMINATED
Registry status
Phase 4
Development phase
1 participants
Enrollment target

Study Summary

The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo. The hypothesis for this study is that subjects receiving daily doses of sitagliptin in combination with their regular antihyperglycemic medications will result in increased healing rates as well as a greater number of healed wounds as compared to subjects receiving placebo and their regular antihyperglycemic medications.

Interventions

  • DRUG Placebo
  • DRUG Sitagliptin

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2014-01
Est. Completion 2015-01
Phase Phase 4

Sponsor

Georgetown University

227 total trials

What the Registry Record Tells You About NCT02015910

The ClinicalTrials.gov registry entry for NCT02015910 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02015910 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02015910 about?

NCT02015910 is a clinical study titled "Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers". The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo. The hypothesis for this study is that subjects receiving daily doses of sitagliptin in combinati...

What is the current status of trial NCT02015910?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2014-01. Estimated completion is 2015-01.

What interventions are being tested in trial NCT02015910?

The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG).

Who is sponsoring clinical trial NCT02015910?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.